SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-263749
Filing Date
2019-10-07
Accepted
2019-10-07 16:06:14
Documents
13
Period of Report
2019-10-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d814241d8k.htm   iXBRL 8-K 37697
2 EX-10.1 d814241dex101.htm EX-10.1 56979
  Complete submission text file 0001193125-19-263749.txt   235557

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20191001.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20191001_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20191001_pre.xml EX-101.PRE 11405
14 EXTRACTED XBRL INSTANCE DOCUMENT d814241d8k_htm.xml XML 3333
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 191140976
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences